We are redirecting you to the source. If you are not redirected in 3 seconds, please click here.

Co-founder in Residence, Next Generation Therapeutics for Parkinson's Disease at Deep Science Ventures. ABOUT THE ROLE. At DSV we’re looking for future Founders, entrepreneurially minded individuals with industry-specific technical and commercial domain expertise eager to solve urgent unmet challenges through venture building.. You will join DSV’s venture creation programme as a Founder in Residence and work closely with the DSV team, using . our methodology. , to spin-out a new company. During the programme, you’ll work on all aspects related to venture creation in this opportunity area, including working out the optimal approach to solve for the desired outcome, building a team and building a viable business case. Once the new venture is incorporated with pre-seed investment from DSV, you and your co-founders will own the majority stake in the business and continue receiving support from the DSV team post-spinout.. The role is full-time, fully remote until venture incorporation and spin-out, after - TBD. . THE OPPORTUNITY AREA. Over 6 million individuals live with Parkinson’s disease (PD) today, and this number is projected to reach 12 million globally by 2040 as populations age. Whilst current therapies do offer symptomatic relief from debilitating motor symptoms, no clinically approved drug intervenes at root cause, meaning disease progression cannot be prevented. In addition, emerging therapeutics which show great promise in animal models of PD often fail to translate in the clinical setting, with even the most successful clinical trials reporting incremental benefit, often capped by dose limiting toxicity. . To address this, we are partnering with Parkinson’s UK to develop precise, next generation therapies which target true disease modifying nodes in previously unimagined ways. As PD is a multi-pathway pathology, spanning oxidative stress, impaired autophagy, mitochondrial dysfunction and neuroinflammation, the efficacy of single pathway approaches is constrained. . OUR APPROACH . We are designing a  therapeutic approach that will target master homeostatic regulators which can simultaneously correct numerous PD pathways, changing the course of disease. We believe this has the potential to transform patient lives by slowing, halting or even reversing disease progression. This pathway has been the focus of drug development in the past but not been drugged successfully through classic approaches. We are looking to unlock this through the use of novel modalities and a clever target selection and targeting strategy that has the potential to overcome the many feedback looks regulating this pathway. . WHO SHOULD APPLY. Essential (must-have):. . PhD in neuroscience or other field relevant to the project;. . Extensive, systems-level knowledge of Parkinson’s disease, including at the cellular and molecular level;. . Expertise in oxidative stress and/or neuroprotective pathways; . . Experience in cellular, molecular and/or biochemical approaches to drug discovery for CNS disorders;. . Experience working in biotech/pharma or an alternative setting which requires strong commercial awareness and understanding of the drug development process;. . Entrepreneurial spirit, likely demonstrated through impactful innovation;. . You are innovative, creative, and guided by first-principles thinking;. . You are highly motivated to create curative solutions for PD patients.. . Preferred (nice-to-have):. . Broad knowledge of brain-specific drug delivery techniques;. . Experience in nucleic acid based payloads (ASO/siRNA/DNA) and delivery techniques;. . Track record of high quality publications in the field, or thought leadership in the field;. . High level industry experience in either pharma, biotech, scientific start-ups, life sciences consulting, life sciences VC, or have previously been an inventor/contributor on patents, etc.;. . Fundraising experience at seed and Series A stages, with established investor contacts.. . Company Location: United Kingdom.